

VIVALDIS V
Animal Health

Pet smile

EDITION- 164



LASER THERAPY: THE FUTURE OF VETERINARY NEUROLOGY


Neurological disorders account for an estimated 5–10% of veterinary consultations, often requiring long-term, multimodal management to restore mobility, reduce pain, and improve quality of life. An emerging advancement in veterinary neurology is photobiomodulation (laser therapy), a non-invasive treatment that complements conventional therapies such as medication, surgery, and rehabilitation. By enhancing mitochondrial ATP production, reducing neuroinflammation and oxidative stress, improving microcirculation, supporting axonal regeneration, and modulating neuropathic pain pathways, laser therapy has shown promising potential in conditions including intervertebral disc disease (IVDD), peripheral nerve injuries, degenerative myelopathy, stroke, cognitive dysfunction, and spinal cord trauma. Clinical case reports have demonstrated encouraging outcomes, with patients regaining mobility, pain perception, continence, and functional recovery when laser therapy was integrated into comprehensive rehabilitation protocols. While it is not a replacement for standard neurological treatment, photobiomodulation is emerging as a valuable evidence-supported adjunct that may accelerate recovery, enhance patient comfort, and improve long-term neurological outcomes. As veterinary medicine continues to embrace regenerative and technology-driven therapies, laser therapy is becoming an important addition to the future of neurological care in companion animals.



IMEXION
3 x 10 tablets



L - SAMETINE
200 ml



Curcupet
3 x 10 tablets



ALZER
150 ml

REDEFINING HOW THE LIVER HEALS AFTER SURGERY

For decades, plasminogen activator inhibitor-1 (PAI-1) was believed to support liver regeneration after surgery. However, a groundbreaking study by researchers from Michigan State University and Mayo Clinic challenges this long-held belief. Using advanced genetic and molecular techniques, the team discovered that PAI-1 actually suppresses the liver's natural regenerative process by limiting the activity of vascular endothelial growth factor (VEGF)—a key protein responsible for promoting blood vessel formation and tissue repair. Remarkably, the study also demonstrated that tranexamic acid (TXA), a medication already widely used to reduce surgical bleeding, restored VEGF activity, enhanced liver regeneration, and reduced the risk of post-hepatectomy liver failure in preclinical models. These findings not only reshape our understanding of liver biology but also open the door to repurposing an established, cost-effective drug to improve recovery after liver surgery. If validated in clinical trials, this approach could significantly enhance surgical outcomes and accelerate healing for patients undergoing liver resection.



Unomarin
100 ml, 50 ml



Prolivet
10 tablets



HEPATIC SUPPORT
2 kg

FDA EXPANDS THE FIGHT AGAINST NEW WORLD SCREWORM WITH EMERGENCY AUTHORIZATION

As the threat of New World screwworm (*Cochliomyia hominivorax*) continues to grow, the U.S. FDA has granted an Emergency Use Authorization (EUA) for F10 Antiseptic Barrier Ointment with Insecticide, providing veterinarians with an important new tool to prevent and treat screwworm infestations (myiasis). The topical formulation combines benzalkonium chloride, polyhexanide, and cypermethrin to protect wounds, control bacterial contamination, and prevent larval invasion. The authorization covers a broad range of species, including cattle, sheep, goats, horses, deer, wild and pet birds, and captive exotic and zoo mammals, although it is not authorized for dogs and cats. Unlike spray formulations, the ointment offers prolonged protection for localized wounds and difficult-to-treat areas, making it particularly valuable in field conditions. This EUA is part of the FDA's broader emergency response to strengthen preparedness against the re-emergence of New World screwworm, emphasizing the importance of early wound management, rapid intervention, and integrated parasite control in safeguarding livestock, wildlife, and animal health.



SPRAD®
1 x 5 ml



VIVALDIS CORNER

We are proud to introduce Imexion (Imepitoin), an innovative treatment designed for the management of idiopathic epilepsy in dogs. Imexion offers veterinarians another valuable option in managing one of the most common neurological disorders in canine practice.

FOR EFFECTIVE MANAGEMENT OF IDIOPATHIC EPILEPSY IN DOGS

1

Mono-therapy



Minimal Sedation



No Dependence



European Medicines Agency Approved



Presentation:
3 x 10 tablets



Seizure Control with a Safer Edge